On February 3, 2022 Amgen (NASDAQ:AMGN) reported that it will host a virtual Business Review Meeting at 8:00 a.m. ET on Tuesday, Feb. 8, 2022 (Press release, Amgen, FEB 3, 2022, View Source [SID1234607682]). Robert A. Bradway, chairman and chief executive officer, along with other members of Amgen’s management team, will present a comprehensive review of the company’s strategy, operations, pipeline, research capabilities and growth outlook. The Business Review Meeting will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast, as with other selected webcasts and presentations regarding developments in Amgen’s business given at certain investor and medical conferences, can be accessed on Amgen’s website, www.amgen.com, under the Investors tab.

Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.